U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT06880601) titled 'Teclistamab Plus ALI for the Treatment of R/R Multiple Myeloma' on March 14.
Brief Summary: The goal of this clinical trial is to evaluate the efficacy of teclistamab and autologous lymphocyte infusions (ALI) in relapse refractory multiple myeloma. The main question it aims to answer is: which is the Duration of response (DoR) with Teclistmab and ALI?
Participants will receive Te for 5 cycles. Participants in PR or better after the first five cycles of Te monotherapy will continue treatment with Te in combination with ALI administration starting from cycle 6
Study Start Date: Nov. 01, 2025
Study Type: INTERVENTIONAL
Condition: ...